We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Agreement to Develop, Market Integrated Digital Pathology Solutions

By LabMedica International staff writers
Posted on 26 Apr 2011
Royal Philips Electronics (Eindhoven, The Netherlands) and NEC Corporation (Tokyo, Japan) have signed an agreement under which the two companies will jointly develop and market highly integrated digital pathology solutions.

Initially targeted to assist in the grading of breast cancer and prostate cancer, the solutions will be based around Philips' new high-throughput pathology slide scanner and NEC's e-Pathologist Cancer Diagnosis Assistance System. More...
They will be designed to use advanced digital techniques to add quantitative analysis to the qualitative information derived from the visual inspection of pathology slides, which is currently the standard procedure.

When a lesion is suspected to be cancerous or precancerous, the normal procedure is to remove a sample of tissue from it and send it to a pathology lab for examination. A thin section of the tissue is mounted on a glass slide, stained to highlight various structures, and visually examined under a microscope.

Philips' ultra-fast slide scanner, which is already commercially available in Europe for research purposes only, employs a unique "continuous autofocus" technology that accurately follows height variations in the tissue surface over horizontal distances as short as 30 µm, allowing extremely high definition full-slide images to be captured in less than one minute per slide.

NEC's e-Pathologist system will detect tissue and cell features within these images in order to identify regions of interest and make quantitative measurements of key structures in conventionally stained (hematoxylin and eosin) tissue samples, or samples stained with immunohistochemistry reagents. These quantitative measurements should assist pathologists in making decisions relating to the clinical treatment of cancer in individual patients.

Philips and NEC aim to produce initial development results from their joint development in digital pathology within the current year.

Related Links:

Royal Philips Electronics
NEC Corporation




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.